ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ASRT Assertio Holdings Inc

1.0398
0.0298 (2.95%)
03 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Assertio Holdings Inc NASDAQ:ASRT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.0298 2.95% 1.0398 1.02 1.05 1.04 0.9901 1.01 601,274 23:26:38

Assertio Therapeutics to Report Second Quarter 2019 Financial Results After The Close of Markets on Wednesday, August 7, 201...

17/07/2019 9:05pm

GlobeNewswire Inc.


Assertio (NASDAQ:ASRT)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Assertio Charts.

Assertio Therapeutics, Inc. (NASDAQ:ASRT) today announced that it will release second quarter 2019 financial results on Wednesday, August 7, 2019, after the close of markets. Following the announcement, the Company will host a conference call beginning at 4:30 p.m. ET to discuss its results.

Participants can access the live webcast from the Investor Relations section of Assertio's website at http://investor.assertiotx.com. Please access the website 15 minutes prior to the start of the call to download and install any necessary audio software.

Audio Conference Call:

U.S. Dial-in Number:1-877-550-3745
International Dial-in Number: 1-281-973-6277
Conference ID:7769879

An archived webcast replay will be available on the Company's website accessed by visiting http://investor.assertiotx.com.

About Assertio Therapeutics, Inc.Assertio Therapeutics is committed to providing responsible solutions to advance patient care in the Company’s core areas of neurology, orphan and specialty medicines. Assertio currently markets three FDA-approved products and continues to identify, license and develop new products that offer enhanced options for patients that may be underserved by existing therapies. To learn more about Assertio, visit www.assertiotx.com.

Investor and Media Contact:John B. Thomas Senior Vice President, Investor Relations and Corporate Communications jthomas@assertiotx.com

1 Year Assertio Chart

1 Year Assertio Chart

1 Month Assertio Chart

1 Month Assertio Chart

Your Recent History

Delayed Upgrade Clock